Chronic Disease Management Market Research Report - Forecast till 2027

Chronic Disease Management Market Research Report: By Solution (Educational Solution, Implementation Solution, Consulting Solution and others), Delivery Mode (Cloud-Based, On-Premises and Web-Based), Application (Arthritis, Cardiovascular Disease, Cancer, Diabetes and others), End-User (Providers, Payers) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027

ID: MRFR/HS/0475-HCR | February 2021 | Region: Global | 90 pages

Request a Free Sample

Impact of COVID- 19 on Chronic Disease Management Market

The impact of COVID-19 on the economy will affect not just people’s income but also their health. A team from the Northwell Health COVID-19 Research Consortium and the Feinstein Institutes for Medical Research collected data on the patients from the enterprise EHR reporting database. In the largest study of hospitalized COVID-19 patients in the US, researchers leveraged EHR data to find that hypertension, diabetes, and obesity are key chronic diseases in the acuity of the virus. Researchers found that of the 2,634 patients studied, 56.6 percent had hypertension, 41.7 percent had obesity, and 33.8 percent had diabetes – the most common comorbidities among the research subjects.

Source: Northwell Health COVID-19 Research Consortium, the Feinstein Institutes for Medical Research, MRFR Analysis

According to the Department of Health and Social Care, in England, the treatment and care of people with chronic diseases account for an estimated 70% of total health and social care expenditure. Around one in three of the population currently have at least one long-term health condition. Currently, most of the resources and expenditures are allocated for the mitigation of the pandemic. This is expected to delay the treatment of patients suffering from chronic diseases.

India accounts for approximately one-quarter of the world’s TB burden, with the estimated number of new TB cases in 2018 at 2,800,000. To curb the spread of COVID-19, the Indian Government announced a nationwide lockdown in March 2020. The lockdown is a major hurdle to TB patients seeking health care and may result in a delay in diagnosis, treatment interruptions, and disease transmission in household contacts. Lockdown has also forced many migrant workers to return to their homes, leading to treatment interruption. Many health facilities are turning to the use of digital platforms to make medical care accessible in difficult to reach areas. To eliminate TB by 2025, a greater number of pharmaceutical companies will need to work in congruence with healthcare providers. A study published by researchers at two universities in Taiwan and the Johns Hopkins Bloomberg School of Public Health following the 2002-2004 SARS outbreak suggested that chronic-care hospitalizations for diabetes plummeted during the crisis but skyrocketed afterward. Health experts are worried that similar problems could crop up because of the Covid-19 pandemic.

During Italy's national lockdown for COVID-19, official hospital statistics in the period March 1–27, 2020, showed substantial decrease—ranging from 73% to 88%—in pediatric emergency department visits compared with the same time in 2019 and 2018. The fall in the number of visits to pediatric emergency departments across five hospitals in Italy.

Source: The Lancet, MRFR Analysis

Startups are pushing to educate people with chronic conditions about COVID-19.

Comcast health tech spinout Quil recently unveiled a tool that helps elective surgery patients stay on track until their operations are rescheduled

Virta and another diabetes-focused digital health company, Omada, have started hosting webinars and creating special patient groups to keep people informed

Clover is using an algorithm to pinpoint the patients most at risk of infection. Clover’s clinicians are using that to reach out to certain patients and suggest patients avoid places where they would be likely to be exposed to infection

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION

6.1. Overview

6.2. Educational Solution